DTech Liquidating

DTech Liquidating Debt/Market Cap

Delisted

The Debt to Market Capitalization Ratio of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is 157,142.86 %. In the previous year, Debt to Market Capitalization Ratio was 571,428.57 % — a change of -72.50% (lower).

Debt/Market Cap

157,142.86 %

YoY

-72.50%

Last updated:

Debt to Market Capitalization Ratio of DTech Liquidating is 2023 157,142.86 % . Debt to Market Capitalization Ratio of DTech Liquidating was 2022 571,428.57 % . It decreases by -72.50% lower compared to the previous year.

The DTech Liquidating Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
0.00 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
857,142.86 USD
Jan 1, 2021
857,142.86 USD
Jan 1, 2022
571,428.57 USD
Jan 1, 2023
157,142.86 USD
The DTech Liquidating Debt/Market Cap history
YEARDebt/Market CapYoY
157,142.86 %-72.50%
571,428.57 %-33.33%
857,142.86 %0.00%
857,142.86 %—
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Debt to Market Capitalization Ratio of DTech Liquidating is 157,142.86 % in 2023.

Debt to Market Capitalization Ratio of DTech Liquidating changed from 571,428.57 % to 157,142.86 %, representing a -72.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's DTech Liquidating with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — DTech Liquidating

All Key Metrics — DTech Liquidating